BB Biotech

BION.SWPre-clinical

BB Biotech AG is a leading investment firm specializing in the global biotechnology industry, listed on the SIX Swiss Exchange. Its strategy involves identifying and investing in promising, publicly traded biotech companies with late-stage clinical assets or recently launched innovative drugs. The company aims to generate long-term capital appreciation by leveraging its deep sector expertise and active portfolio management, offering shareholders a unique vehicle to participate in the value creation of the biotech sector.

Market Cap

$3.2B

Employees

10-50

Focus

Biotech

BION.SW · Stock Price

USD 45.4019.30 (-29.83%)

Historical price data

AI Company Overview

Technology Platform

BB Biotech is an investment company and does not own a technology platform. Its core competency is active portfolio management and deep fundamental analysis of publicly traded biotechnology companies.

Funding History

Total raised: $150M

IPO$150MUndisclosedJun 15, 1993

Opportunities

The primary growth opportunity is capital appreciation through successful stock selection in a biotech sector driven by scientific innovation and unmet medical need.

Additional opportunities include benefiting from industry consolidation (M&A) and the commercial launch of transformative therapies within its portfolio.

Risk Factors

Key risks include high volatility of biotech stocks, clinical trial failures within the portfolio, concentration risk in selected holdings, and the potential for its shares to trade at a discount to net asset value (NAV).

Performance is also sensitive to broader financial market conditions.

Competitive Landscape

BB Biotech competes with other listed biotech investment trusts and passive biotech ETFs. Its differentiation lies in active, concentrated portfolio management by a specialized team with deep scientific and financial expertise, aiming to outperform broader biotech indices.

Publications

Patents